Proteins and Peptides

23 Mar 2021 Zealand Pharma Announces FDA Approval of Zegalogue (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes
22 Mar 2021 Cybrexa Therapeutics Receives Green Light from FDA on Investigational New Drug Application for CBX-12 (alphalex™-exatecan)
22 Mar 2021 Amolyt Pharma Presents First Clinical Data for AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021)
20 Mar 2021 Amyndas Announces Positive Top-Line Phase 2 Results for Investigational AMY-101 in Adults With Periodontal Inflammation and Gingivitis
16 Mar 2021 CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
15 Mar 2021 Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
09 Mar 2021 Affibody and Inmagene announce IND Clearance for izokibep (ABY-035) for the treatment of Non-infectious Non-anterior Uveitis
09 Mar 2021 Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
09 Mar 2021 AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine
09 Mar 2021 Sesen Bio Submits Marketing Authorization Application to the European Medicines Agency for Vicineum™
09 Mar 2021 Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers
04 Mar 2021 Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
03 Mar 2021 FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
01 Mar 2021 Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126
01 Mar 2021 LFB Announces that the European Medicines Agency (EMA) Has Accepted for Filing the Marketing Authorization Application for eptacog beta (activated), a Recombinant Coagulation Factor VIIa
01 Mar 2021 Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
28 Feb 2021 EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
25 Feb 2021 I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
23 Feb 2021 NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
23 Feb 2021 Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity
17 Feb 2021 Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
17 Feb 2021 Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
16 Feb 2021 Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™
16 Feb 2021 ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071
15 Feb 2021 Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up